|
Patent landscape, scope, and claims: |
United States Patent 9,155,705: Scope, Claim Coverage, and US Patent Landscape for a Metformin-L-Arginine Fixed-Dose Tablet With a Xanthine Derivative
What does US 9,155,705 claim cover?
US Drug Patent 9,155,705 claims a solid oral pharmaceutical composition built around a specific xanthine derivative plus metformin hydrochloride and L-arginine, with defined dose ranges, excipient architecture, and tablet/process limitations.
Core claimed actives (identity is fixed)
The patent’s composition is anchored to the compound:
- 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
Claimed co-actives:
- Metformin hydrochloride
- L-arginine (specifically about 1 mg to about 50 mg per dosage form)
Core dosage architecture (numeric ranges are fixed)
The claimed composition requires:
- Xanthine derivative: about 0.5 mg to about 10 mg
- Metformin hydrochloride: about 100 mg to about 1500 mg (with strength-specific claim fallbacks)
- L-arginine: about 1 mg to about 50 mg
Excipients and dosage form are also constrained
Claims further limit:
- Solid pharmaceutical composition (not injectables, not liquids)
- Tablet variants include mono-layer, bi-layer, press-coated, and film-coated tablets
- Excipient categories: filler, binder, lubricant, glidant
- Binder-specific claim: copovidone (Claim 9)
- Particle size constraint appears in Claim 14: X90 < 200 μm for the xanthine derivative
Relationship constraint (weight ratio)
The patent includes a cross-component ratio requirement:
- L-arginine : xanthine derivative weight ratio: about 1:20 to about 10:1 (Claim 7)
What are the most important claim drivers for infringement?
The risk is concentrated in three claim elements that are hard to design around without changing formulation and labeling:
-
Exact xanthine derivative identity
- Claims repeatedly recite the specific chemical name. A different analog is unlikely to meet literal scope.
-
Presence and dose range of L-arginine
- L-arginine is not incidental; it is a required component with a defined dose band (1 mg to 50 mg) and ratio constraint (Claim 7).
- Design-around by removing L-arginine is the most direct path, but may break the fixed-dose strategy and clinical rationale.
-
Metformin hydrochloride in defined dose ranges
- The composition is metformin-based with a broad range (100 mg to 1500 mg) and multiple strength-specific claims (250, 500, 625, 750, 850, 1000 mg; plus subset claims for 500/850/1000).
Claim set map by “coverage depth”
Below is how the claims scale from broad to narrow:
A. Broad base claim (Claim 1)
- Requires all three components with broad dose bands:
- Xanthine: 0.5–10 mg
- Metformin HCl: (not fully shown in Claim 1 text, but Claim 4/5/6 define ranges and strengths)
- L-arginine: 1–50 mg
- Plus excipient and tablet context
B. Strength-specific dependent claims (Claims 2, 3, 4, 5, 6)
- Xanthine derivative dosage strengths explicitly enumerated:
- 0.5, 1, 2.5, 5, 10 mg (Claim 2)
- 2.5 mg (Claim 3)
- Metformin HCl strengths enumerated:
- Strength range: 100–1500 mg (Claim 4)
- Specific strengths: 250, 500, 625, 750, 850, 1000 mg (Claim 5)
- Specific set: 500, 850, 1000 mg (Claim 6)
C. Ratio and excipient/particle tailoring (Claims 7–10, 14)
- Ratio constraint: 1:20 to 10:1 (Claim 7)
- Excipient selection: filler/binder/lubricant/glidant (Claim 8)
- Binder specifically: copovidone (Claim 9)
- Optional addition: corn starch, magnesium stearate, colloidal anhydrous silica (Claim 10)
- Particle size: X90 < 200 μm (Claim 14)
D. Tablet architecture and composition breadth (Claims 11–13, 19–24)
- Tablet type: mono-layer, bi-layer, press-coated, film-coated (Claim 11)
- Film-coated film coat noted (Claim 12)
- Claim 13 adds more explicit excipient list (filler, binder, glidant, lubricant)
E. Process claim element (Claim 15)
- Requires a process of “incorporating active ingredients” and L-arginine using specified excipient set including:
- D-mannitol, corn starch, pregelatinized starch, copovidone, magnesium stearate, colloidal anhydrous silica
F. Multi-excipient formulation constraints (Claims 16–18, 20–23, 24–25)
- Excipient combinations by category:
- filler (Claim 16)
- filler + binder (Claim 17)
- filler + binder + lubricant (Claim 18)
- filler + binder + lubricant + glidant (Claim 23)
- Most concrete excipient matrix (Claim 24) and narrow strength combination (Claim 25)
Which claims are the narrowest and most design-around sensitive?
The tightest coverage typically comes from “stacked” constraints: exact dosage strength + excipient identity + tablet form + particle size or ratio.
Narrowest-by-limitation claims
- Claim 3: xanthine derivative is 2.5 mg
- Claim 6: metformin HCl is 500 mg, 850 mg, or 1000 mg
- Claim 9: binder is specifically copovidone
- Claim 14: xanthine derivative particle distribution X90 < 200 μm
- Claim 24: specific excipient set:
- excipients are corn starch, copovidone, magnesium stearate, colloidal anhydrous silica
- Claim 25: tightly constrained composition band:
- xanthine 2.5 mg
- metformin HCl 0.5–10 mg (as written in your excerpt; this is internally inconsistent with Claim 4/5/6 bands, but the claim text you provided is controlling for this exercise)
- L-arginine 1–25 mg
- plus a “tablet” presentation
What that means for product design
Even if a candidate formulation misses one dependent limitation (for example, binder choice), it can still fall within broad independent coverage if it meets the base requirements (Claims 1 and the key component dose bands). Conversely, if a product hits the independent claim but differs in binder or particle size, the dependent claims may not read on it, but the base infringement risk remains.
How does the excipient architecture affect the patent’s practical enforceability?
The patent’s excipient language is a mix of functional categories and explicit materials.
Category-based excipient claims
- Claim 8: excipient selected from group of fillers, binders, lubricants, glidants.
- Claims 16–18 and Claims 20–23: excipient set combinations defined by category.
These still leave manufacturing flexibility because the claims accept “one or more” from each category and only add specificity when a binder is selected (copovidone) or an excipient list is enumerated.
Material-specific excipient claims
- Copovidone is explicitly called out (Claim 9).
- Corn starch, magnesium stearate, colloidal anhydrous silica are called out as optional components (Claim 10) and as part of the defined excipient set in Claim 24.
A generic tablet recipe is at moderate risk if it uses common co-processing excipients that match those lists. A manufacturer choosing an alternative binder or excluding those named excipients can aim to reduce dependent-claim exposure, though not necessarily independent-claim exposure.
What is claimed about tablet form and particle attributes?
Tablet format
- Claim 11: tablet can be mono-layer, bi-layer, press-coated, or film-coated (for drug-loading).
- Claim 12: tablet comprises a film coat.
So “just film-coat it” does not avoid the patent if the composition matches actives/doses/excipient categories.
Particle size
- Claim 14: xanthine derivative must have X90 < 200 μm.
- This can matter for:
- milling targets
- screening cutoffs
- specification limits for the API/graded fraction
If a product purposely sets particle size outside that distribution, it may avoid Claim 14 while still potentially infringing other claims.
Does the patent claim manufacturing process as well as the composition?
Claim 15 adds a process constraint:
- process includes incorporating actives and L-arginine in a pharmaceutical excipient selected from:
- D-mannitol, corn starch, pregelatinized starch, copovidone, magnesium stearate, colloidal anhydrous silica
This can be relevant if litigation focuses on manufacturing method or if evidence of process parameters is available.
What is the patent landscape risk profile in the US for a product like this?
Based on the claims alone, the enforcement risk clusters around:
- Fixed-dose combination: xanthine derivative + metformin + L-arginine
- Oral solid dosage: tablets
- Specified formulation features: excipient families, copovidone binder, enumerated strengths, particle size
Likely contention points in US generic or reformulation efforts
-
Component omission or substitution
- The cleanest noninfringement path is removing L-arginine or replacing it with a compound not covered.
- Substituting the xanthine derivative with a different analog would also likely avoid literal scope.
-
Dose band nonconformance
- If the product dosage falls outside:
- xanthine 0.5–10 mg
- L-arginine 1–50 mg
- metformin range/strengths
it may avoid claim reading entirely.
-
Weight ratio nonconformance
- Claim 7 imposes ratio bounds (1:20 to 10:1). A formulation that stays within dose bands but pushes the ratio outside that band can potentially avoid Claim 7 while still meeting Claims 1 if Claim 1 does not inherently include the ratio.
-
API particle spec manipulation
- Claim 14 is a spec-driven limitation that can be engineered (set X90 at or above 200 μm). That affects dependent-claim exposure.
-
Excipient substitutions
- Avoiding copovidone and the specific excipient sets listed in Claims 10 and 24 may reduce dependent-claim coverage.
What are the key business implications of the claim structure?
1) The patent is designed for fixed-dose coadministration, not monotherapy
The combination requirement is strict:
- xanthine derivative + metformin HCl + L-arginine must be in one solid dosage form.
That structure is typical of patents meant to block “single-tablet” combination entries while allowing separate-product pathways (unless another patent covers separate administration schedules or specific co-therapies).
2) The claims include multiple “fallbacks” that preserve value across strength tiers
The enumerated strengths (xanthine and metformin) widen coverage for:
- different tablet strength presentations
- dose titration schedules
A challenger cannot evade by choosing a different strength within the enumerated set.
3) Dependent claims target common formulation choices
- copovidone binder (Claim 9)
- starch/lubricant/glidant combinations (Claims 10 and 24)
- film-coating (Claims 11–12)
These are common in solid dosage manufacturing and therefore increase the chance that generic formulations align.
Claim-by-claim coverage highlights (US 9,155,705 excerpt)
| Claim |
Coverage element |
What it locks down |
| 1 |
Independent composition |
Solid composition with the exact xanthine derivative, metformin HCl, excipient, and L-arginine; xanthine dose 0.5–10 mg and L-arginine 1–50 mg |
| 2 |
Xanthine strength list |
xanthine dose is 0.5/1/2.5/5/10 mg |
| 3 |
Specific xanthine strength |
xanthine is 2.5 mg |
| 4 |
Metformin dose range |
metformin HCl is 100–1500 mg |
| 5 |
Metformin strength list |
metformin HCl is 250/500/625/750/850/1000 mg |
| 6 |
Subset strengths |
metformin HCl is 500/850/1000 mg |
| 7 |
Ratio bound |
xanthine : L-arginine weight ratio 1:20 to 10:1 |
| 8 |
Excipient category |
filler/binder/lubricant/glidant (functional group) |
| 9 |
Binder specific |
copovidone binder |
| 10 |
Specific excipient options |
corn starch, magnesium stearate, colloidal anhydrous silica |
| 11 |
Tablet form types |
mono-layer, bi-layer, press-coated, film-coated |
| 12 |
Film-coat limitation |
tablet comprises a film coat |
| 13 |
Explicit excipient categories |
filler, binder, glidant, lubricant |
| 14 |
Particle size spec |
xanthine API X90 < 200 μm |
| 15 |
Process limitation |
process uses excipient selected from D-mannitol, corn starch, pregelatinized starch, copovidone, magnesium stearate, colloidal anhydrous silica |
| 16 |
Excipient includes filler |
filler requirement |
| 17 |
Excipient includes filler + binder |
filler + binder required |
| 18 |
Excipient includes filler + binder + lubricant |
adds lubricant requirement |
| 19 |
Tablet formulation restatement |
tablet with the same core actives and excipient set |
| 20–23 |
Excipient set combinations |
progressively adds binder/lubricant/glidant |
| 24 |
Explicit excipient set |
corn starch + copovidone + magnesium stearate + colloidal anhydrous silica |
| 25 |
Specific strength and partial ranges |
tablet with xanthine 2.5 mg, L-arginine 1–25 mg, plus metformin band as written in excerpt |
Key Takeaways
- US 9,155,705 claims a tablet combining a specific xanthine derivative with metformin hydrochloride and L-arginine, with fixed dose bands and multiple strength fallbacks.
- The highest infringement risk comes from meeting Claim 1 (core combination + dose ranges), then unintentionally matching dependent constraints like:
- copovidone binder (Claim 9)
- film-coated tablets (Claims 11–12)
- particle size X90 < 200 μm (Claim 14)
- enumerated metformin and xanthine strengths (Claims 2–6)
- Patent design is combination-centric: omitting L-arginine or replacing the xanthine derivative are the strongest design-around levers; formulation tweaks mainly reduce dependent-claim coverage rather than eliminating the base claim if doses and actives remain within range.
- The landscape implication for US entry strategy is that generic or reformulation efforts must manage both formulation composition and spec/batch controls tied to particle distribution and excipient identity.
FAQs
-
What is the independent claim’s composition requirement in US 9,155,705?
A solid (tablet) pharmaceutical composition containing the specific xanthine derivative (0.5–10 mg), metformin hydrochloride, an excipient, and L-arginine (1–50 mg).
-
Does the patent require a particular tablet type like film-coated?
No. Film-coated tablets are covered via dependent claims (Claims 11–12), but Claim 1 covers solid pharmaceutical compositions generally.
-
What excipient is explicitly singled out as a binder?
Copovidone (Claim 9).
-
What particle size limitation is included?
The xanthine derivative’s particle size must satisfy X90 < 200 μm (Claim 14).
-
What is the weight ratio limitation involving L-arginine and the xanthine derivative?
About 1:20 to about 10:1 (Claim 7), expressed as the weight ratio range stated in the claim.
References
[1] United States Patent No. 9,155,705.
More… ↓
⤷ Start Trial
|
